Medical Hypotheses
Volume 58, Issue 2 , Pages 127-132, February 2002

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia

  • M.J. Fryer

      Affiliations

    • Correspondence to: Michael J. Fryer, PhD, Department of Biological Sciences, John Tabor Laboratories, University of Essex, Wivenhoe Park, Colchester, Essex CO4 3SQ, UK. Phone: +44 (0)1206 873333; Fax: +44 (0)1206 873416; E-mail: mfryer@essex.ac.uk

John Tabor Laboratories, University of Essex, Colchester, UK

Received 2 March 2001; accepted 5 July 2001.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0306-9877(01)91474-4

doi:10.1054/mehy.2001.1474

Medical Hypotheses
Volume 58, Issue 2 , Pages 127-132, February 2002

Article Tools